554453-19-9

Usage

Uses

Used in Chemical Research and Development:
1H-Pyrrolo[3,2-b]pyridine-3-acetonitrile is used as a research compound for its unique structural properties, which can be explored for various applications in the field of chemistry. Its potential uses may include the synthesis of new compounds, the study of its reactivity, or as a building block in the development of novel materials. 1H-Pyrrolo[3,2-b]pyridine-3-acetonitrile's properties, such as its stability and solubility, make it a valuable asset in the realm of chemical research.

InChI:InChI=1/C9H7N3/c10-4-3-7-6-12-8-2-1-5-11-9(7)8/h1-2,5-6,12H,3H2

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 
• 773837-37-9 sodium cyanide 
• 23612-34-2 N,N-dimethyl-1-(1H-pyrrolo[3,2-b]pyridin-3-yl)methanamine 

Downstream Products

• 1312891-85-2 (E)-3-(4-{[2-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethylamino]methyl}phenyl)acrylic acid methyl ester 
• 1312891-47-6 (E)-N-hydroxy-3-(4-{[2-(1H-pyrrolo[3,2-b]pyridin-3-yl)ethylamino]methyl}phenyl)acrylamide 
• 28419-74-1 2-[1H-pyrrolo [3,2-b]pyridin-3-yl]ethan-1-amine 

Relevant academic research and scientific papers

INDOLE AHR INHIBITORS AND USES THEREOF

The present invention provides compounds useful as inhibitors of AHR, compositions thereof, and methods of using the same.

FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE

Described herein are fused bicyclic compounds, compositions, and methods for their use for the treatment of disease.

Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors

Histone deacetylase (HDAC) inhibitors have shown promise in treating various forms of cancer. However, many HDAC inhibitors from diverse structural classes have been associated with QT prolongation in humans. Inhibition of the human ether a-go-go related gene (hERG) channel has been associated with QT prolongation and fatal arrhythmias. To determine if the observed cardiac effects of HDAC inhibitors in humans is due to hERG blockade, a highly potent HDAC inhibitor devoid of hERG activity was required. Starting with dacinostat (LAQ824), a highly potent HDAC inhibitor, we explored the SAR to determine the pharmacophores required for HDAC and hERG inhibition. We disclose here the results of these efforts where a high degree of pharmacophore homology between these two targets was discovered. This similarity prevented traditional strategies for mitigating hERG binding/modulation from being successful and novel approaches for reducing hERG inhibition were required. Using a hERG homology model, two compounds, 11r and 25i, were discovered to be highly efficacious with weak affinity for the hERG and other ion channels.